Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pico-Tesla Magnetic Therapies LLC

This article was originally published in Start Up

Executive Summary

Pico-Tesla Magnetic Therapies LLC's [noninvasive neuromodulation platform uses low levels of electromagnetic field to improve signs and symptoms of Parkinson's disease. The field strengths used by the company's Resonator device are in orders of magnitude below those utilized in MRI scanners or transcranial magnetic stimulators and thus should present no risk to patients.

You may also be interested in...



Start-Up Previews (12/2009)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Bringing New Blood to the Anemia Market," features profiles of Akebia, Neumedicines and Palkion. Plus these Start-Ups Across Health Care: Aterovax, Pico-Tesla Magnetic Therapies, SpineAlign Medical, Theraclion, Virdante Pharmaceuticals and Zacharon Pharmaceuticals.

California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation

CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037592

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel